Journal of Lipid Research, Vol 38, 373-390, Copyright © 1997 by Lipid Research, Inc.

ARTICLES

Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin

OH Morand, JD Aebi, H Dehmlow, YH Ji, N Gains, H Lengsfeld and J Himber
F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Basel, Switzerland.

2,3-Oxidosqualene:lanosterol cyclase (OSC, E.C. 5.4.99.7) represents a unique target for a cholesterol lowering drug. Partial inhibition of OSC should reduce synthesis of lanosterol and subsequent sterols, and also stimulate the production of epoxysterols that repress HMG-CoA reductase expression, generating a synergistic, self-limited negative regulatory loop. Hence, the pharmacological properties of Ro 48-8.071, a new OSC inhibitor, were compared to that of an HMG-CoA reductase inhibitor, simvastatin. Ro 48-8.071 blocked human liver OSC and cholesterol synthesis in HepG2 cells in the nanomolar range; in cells it triggered the production of monooxidosqualene, dioxidosqualene, and epoxycholesterol. It was safe in hamsters, squirrel monkeys and Gottingen minipigs at pharmacologically active doses, lowering LDL approximately 60% in hamsters, and at least 30% in the two other species, being at least as efficacious as safe doses of simvastatin. The latter was hepatotoxic in hamsters at doses > 30 mumol/kg/day limiting its window of efficacy. Hepatic monooxidosqualene increased dose-dependently after treatment with Ro 48-8.071, up to approximately 20 micrograms/g wet liver or less than 1% of hepatic cholesterol, and it was inversely correlated with LDL levels. Ro 48-8.071 did not reduce coenzyme Q10 levels in liver and heart of hamsters, and importantly did not trigger an overexpression of hepatic HMG-CoA reductase, squalene synthase, and OSC itself. In strong contrast, simvastatin stimulated these enzymes dramatically, and reduced coenzyme Q10 levels in liver and heart. Altogether these findings clearly differentiate the OSC inhibitor Ro 48-8.071 from simvastatin, and support the view that OSC is a distinct key component in the regulation of the cholesterol synthesis pathway.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Bentinger, M. Tekle, K. Brismar, T. Chojnacki, E. Swiezewska, and G. Dallner Polyisoprenoid Epoxides Stimulate the Biosynthesis of Coenzyme Q and Inhibit Cholesterol Synthesis J. Biol. Chem., May 23, 2008; 283(21): 14645 - 14653. [Abstract] [Full Text] [PDF]

				R. Soundararajan, A. D. Wishart, H. P. V. Rupasinghe, M. Arcellana-Panlilio, C. M. Nelson, M. Mayne, and G. S. Robertson Quercetin 3-Glucoside Protects Neuroblastoma (SH-SY5Y) Cells in Vitro against Oxidative Damage by Inducing Sterol Regulatory Element-binding Protein-2-mediated Cholesterol Biosynthesis J. Biol. Chem., January 25, 2008; 283(4): 2231 - 2245. [Abstract] [Full Text] [PDF]

				J. Wong, C. M. Quinn, I. C. Gelissen, and A. J. Brown Endogenous 24(S),25-Epoxycholesterol Fine-tunes Acute Control of Cellular Cholesterol Homeostasis J. Biol. Chem., January 11, 2008; 283(2): 700 - 707. [Abstract] [Full Text] [PDF]

				A. Villagra, N. Ulloa, X. Zhang, Z. Yuan, E. Sotomayor, and E. Seto Histone Deacetylase 3 Down-regulates Cholesterol Synthesis through Repression of Lanosterol Synthase Gene Expression J. Biol. Chem., December 7, 2007; 282(49): 35457 - 35470. [Abstract] [Full Text] [PDF]

				L. Marcoff and P. D. Thompson The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review J. Am. Coll. Cardiol., June 12, 2007; 49(23): 2231 - 2237. [Abstract] [Full Text] [PDF]

				M. M. Beyea, C. L. Heslop, C. G. Sawyez, J. Y. Edwards, J. G. Markle, R. A. Hegele, and M. W. Huff Selective Up-regulation of LXR-regulated Genes ABCA1, ABCG1, and APOE in Macrophages through Increased Endogenous Synthesis of 24(S),25-Epoxycholesterol J. Biol. Chem., February 23, 2007; 282(8): 5207 - 5216. [Abstract] [Full Text] [PDF]

				D. E. Telford, S. M. Lipson, P. H. R. Barrett, B. G. Sutherland, J. Y. Edwards, J. D. Aebi, H. Dehmlow, O. H. Morand, and M. W. Huff A Novel Inhibitor of Oxidosqualene:Lanosterol Cyclase Inhibits Very Low-Density Lipoprotein Apolipoprotein B100 (ApoB100) Production and Enhances Low-Density Lipoprotein ApoB100 Catabolism Through Marked Reduction in Hepatic Cholesterol Content Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2608 - 2614. [Abstract] [Full Text] [PDF]

				J. Wong, C. M. Quinn, and A. J. Brown Statins Inhibit Synthesis of an Oxysterol Ligand for the Liver X Receptor in Human Macrophages With Consequences for Cholesterol Flux Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2365 - 2371. [Abstract] [Full Text] [PDF]

				R. J. Cenedella, R. Jacob, D. Borchman, D. Tang, A. R. Neely, A. Samadi, R. P. Mason, and P. Sexton Direct perturbation of lens membrane structure may contribute to cataracts caused by U18666A, an oxidosqualene cyclase inhibitor J. Lipid Res., July 1, 2004; 45(7): 1232 - 1241. [Abstract] [Full Text] [PDF]

				S. D. Shenoy, T. A. Spencer, N. A. Mercer-Haines, M. Abdolalipour, W. L. Wurster, M. Runge-Morris, and T. A. Kocarek Induction of CYP3A by 2,3-Oxidosqualene:Lanosterol Cyclase Inhibitors Is Mediated by an Endogenous Squalene Metabolite in Primary Cultured Rat Hepatocytes Mol. Pharmacol., May 1, 2004; 65(5): 1302 - 1312. [Abstract] [Full Text]

				S. D. Shenoy, T. A. Spencer, N. A. Mercer-Haines, M. Alipour, M. D. Gargano, M. Runge-Morris, and T. A. Kocarek CYP3A INDUCTION BY LIVER X RECEPTOR LIGANDS IN PRIMARY CULTURED RAT AND MOUSE HEPATOCYTES IS MEDIATED BY THE PREGNANE X RECEPTOR Drug Metab. Dispos., January 1, 2004; 32(1): 66 - 71. [Abstract] [Full Text] [PDF]

				G A Clarke, G Bouchard, B Paigen, and M C Carey Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse Gut, January 1, 2004; 53(1): 136 - 142. [Abstract] [Full Text] [PDF]

				A. H. Rowe, C. A. Argmann, J. Y. Edwards, C. G. Sawyez, O. H. Morand, R. A. Hegele, and M. W. Huff Enhanced Synthesis of the Oxysterol 24(S),25-Epoxycholesterol in Macrophages by Inhibitors of 2,3-Oxidosqualene:Lanosterol Cyclase: A Novel Mechanism for the Attenuation of Foam Cell Formation Circ. Res., October 17, 2003; 93(8): 717 - 725. [Abstract] [Full Text] [PDF]

				H. Hiyoshi, M. Yanagimachi, M. Ito, I. Ohtsuka, I. Yoshida, T. Saeki, and H. Tanaka Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors J. Lipid Res., July 1, 2000; 41(7): 1136 - 1144. [Abstract] [Full Text]

				J. Mitchell and R. J. Cenedella Human Lens Cholesterol Concentrations in Patients Who Used Lovastatin or Simvastatin Arch Ophthalmol, May 1, 1999; 117(5): 653 - 657. [Abstract] [Full Text] [PDF]

				R. G. Gardner, H. Shan, S. P. T. Matsuda, and R. Y. Hampton An Oxysterol-derived Positive Signal for 3-Hydroxy- 3-methylglutaryl-CoA Reductase Degradation in Yeast J. Biol. Chem., March 16, 2001; 276(12): 8681 - 8694. [Abstract] [Full Text] [PDF]